DYN – dyne therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics appoints Erick Lucera as CFO [Seeking Alpha]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer [Yahoo! Finance]
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Form 4 Dyne Therapeutics, Inc. For: Mar 31 Filed by: Lucera Erick
Form 3 Dyne Therapeutics, Inc. For: Mar 31 Filed by: Lucera Erick
Form S-8 Dyne Therapeutics, Inc.
Form 8-K Dyne Therapeutics, Inc. For: Mar 17
Form 4 Dyne Therapeutics, Inc. For: Mar 13 Filed by: Friedl-Naderer Johanna
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.